Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial

Abstract

Fontan surgery is a widely used palliative procedure that significantly improves the survival period of patients with complex congenital heart disease (CHD). However, it does not decrease postoperative complication rate. Previous studies suggested that elevated mean pulmonary artery pressure (mPAP) and vascular resistance lead to decreased exercise tolerance and myocardial dysfunction. Therapy with endothelial receptor antagonists (Bosentan) has been demonstrated to improve the patients’ prognosis. A double-blind, randomized controlled trial was performed to explore the efficacy of Bosentan in treating patients who underwent the Fontan procedure. Eligible participants were randomly divided into Bosentan group and control group. Liver function was tested at a local hospital and the results were reported to the phone inspector every month. If the results suggested abnormal liver function, treatment would be adjusted or terminated. All the participants finished the follow-up study, with no patients lost to follow-up. Unblinding after 2-year follow-up, no mortality was observed in either group. However, secondary end-points were found to be significantly different in the comparable groups. The cardiac function and 6-min walking distance in the Bosentan group were significantly superior to those in the control group (P=0.018 and P=0.027). Bosentan could improve New York Heart Association (NYHA) functional status and improve the results of the 6-min walking test (6MWT) in Fontan patients post-surgery, and no other benefits were observed. Furthermore, a primary meta-analysis study systematically reviewed all the similar clinical trails worldwide and concluded an overall NYHA class improvement in Fontan patients who received Bosentan treatments.

Keywords

Fontan procedure / Bosentan / prognosis / pulmonary hypertension / pulmonary vascular resistance

References

[1] HoseinRB, ClarkeAJ, McGuirkSP, et al. . Factors influencing early and late outcome following the Fontan procedure in the current era. The 'Two Commandments'?. Eur J Cardiothorac Surg, 2007, 31(3): 344-352 PMID: 17236782

[2] McGuirkSP, WinlawDS, LangleySM, et al. . The impact of ventricular morphology on midterm outcome following completion total cavopulmonary connection. Eur J Cardiothorac Surg, 2003, 24(1): 37-46 PMID: 12853043

[3] OnoM, BoethigD, GoerlerH, et al. . Clinical outcome of patients 20 years after Fontan operation—effect of fenestration on late morbidity. Eur J Cardiothorac Surg, 2006, 30(6): 923-929 PMID: 17074498

[4] d'UdekemY, CheungMM, SetyapranataS, et al. . How good is a good Fontan? Quality of life and exercise capacity of Fontans without arrhythmias. Ann Thorac Surg, 2009, 88(6): 1961-1969 PMID: 19932269

[5] ParidonSM, MitchellPD, ColanSD, et al. . A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol, 2008, 52(2): 99-107 PMID: 18598887

[6] MoriM, AguirreAJ, ElderRW, et al. . Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol, 2014, 35(4): 569-579 PMID: 24531876

[7] OvaertC, ThijsD, DewolfD, et al. . The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young, 2009, 19(4): 331-339 PMID: 19519964

[8] HebertA, MikkelsenUR, ThilenU, et al. . Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation, 2014, 130(23): 2021-2030 PMID: 25446057

[9] McLaughlinVV, ArcherSL, BadeschDB, et al. . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol, 2009, 53(17): 1573-1619 PMID: 19389575

[10] LiFF, DuXL, ChenS. Biventricular repair versus uni-ventricular repair for pulmonary atresia with intact ventrical septum: A systematic review. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(5): 656-661 PMID: 26489617

[11] DerkG, HouserL, MinerP, et al. . Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis, 2015, 10(1): E11-16 PMID: 24890846

[12] BowaterSE, WeaverRA, ThorneSA, et al. . The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis, 2012, 7(3): 243-249 PMID: 22348734

[13] SchuuringMJ, VisJC, van DijkAP, et al. . Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail, 2013, 15(6): 690-698 PMID: 23361871

[14] LewisG, ThorneS, CliftP, et al. . Cross-sectional imaging of the Fontan circuit in adult congenital heart disease. Clin Radiol, 2015, 70(6): 667-675 PMID: 25818807

[15] HislopAA. Airway and blood vessel interaction during lung development. J Anat, 2002, 201(4): 325-334 PMID: 12430957 PMCID: 1570917

[16] JiangYL, DaiAG, LiQF, et al. . Transforming growth factor-beta1 induces transdifferentiation of fibroblasts into myofibroblasts in hypoxic pulmonary vascular remodeling. Acta Biochim Biophys Sin (Shanghai), 2006, 38(1): 29-36

[17] HaraA, ChapinCJ, ErtseyR, et al. . Changes in fetal lung distension alter expression of vascular endothelial growth factor and its isoforms in developing rat lung. Pediatr Res, 2005, 58(1): 30-37 PMID: 15879288

[18] PapamatheakisDG, ChunduM, BloodAB, et al. . Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep. Pulm Circ, 2013, 3(4): 757-780 PMID: 25006393 PMCID: 4070839

[19] PengEW, SpoonerR, YoungD, et al. . Acute B-type natriuretic peptide response and early postoperative right ventricular physiology following tetralogy of Fallot's repair. Interact Cardiovasc Thorac Surg, 2012, 15(3): 335-339 PMID: 22685026 PMCID: 3422920

[20] SchuuringMJ, VisJC, BoumaBJ, et al. . Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity?. Contemp Clin Trials, 2011, 32(4): 586-591 PMID: 21527360

[21] RayL, MathieuM, JespersP, et al. . Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol, 2008, 93(3): 434-442 PMID: 17993509

[22] SugimotoM, MasutaniS, SekiM, et al. . High serum levels of procollagen type III N-terminal amino peptide in patients with congenital heart disease. Heart, 2009, 95(24): 2023-2028 PMID: 19666460

[23] GulatiA, JabbourA, IsmailTF, et al. . Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA, 2013, 309(9): 896-908 PMID: 23462786

[24] RebicD, RasicS, RebicV. Influence of endothelin-1 and nitric oxide on left ventricular remodelling in patients on peritoneal dialysis. Ren Fail, 2014, 36(2): 232-236 PMID: 24059246

[25] IshidaH, KogakiS, IchimoriH, et al. . Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients. Int J Cardiol, 2012, 159(1): 34-39 PMID: 21356562

[26] JasminJF, LucasM, CernacekP, et al. . Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation, 2001, 103(2): 314-318 PMID: 11208695

[27] BenzaRL, RayburnBK, TallajJA, et al. . Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest, 2006, 129(4): 1009-1015 PMID: 16608951

[28] BergerRM, BeghettiM, GalieN, et al. . Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J Cardiol, 2010, 144(3): 373-378 PMID: 19464064